@ibrahimazar.bsky.social
Reposted
Molecular Characterization and Clinical Outcomes of Pancreatic Neuroendocrine ... - goo.gl/alerts/YoGGmC #GoogleAlerts
Molecular Characterization and Clinical Outcomes of Pancreatic Neuroendocrine Neoplasms Harboring PAK4-NAMPT Alterations | JCO Oncology Advances
PURPOSEThe mammalian target of rapamycin (mTOR) inhibitor everolimus is US Food and Drug
Administration-approved for advanced pancreatic neuroendocrine neoplasms (pNENs),
yet resistance is common, nec...
goo.gl
May 3, 2025 at 9:58 PM
Molecular Characterization and Clinical Outcomes of Pancreatic Neuroendocrine ... - goo.gl/alerts/YoGGmC #GoogleAlerts